Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large growth in short interest in June. As of June 30th, there was short interest totaling 282,012 shares, a growth of 375.6% from the June 15th total of 59,293 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 392,720 shares, the days-to-cover ratio is presently 0.7 days.

Fresenius SE & Co. Stock Down 2.5%

OTCMKTS FSNUY opened at $11.88 on Tuesday. The stock has a market capitalization of $26.77 billion, a P/E ratio of 15.84 and a beta of 0.63. Fresenius SE & Co. has a 52 week low of $10.33 and a 52 week high of $33.93. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27. The stock has a fifty day moving average of $11.41 and a 200-day moving average of $12.99.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $6.75 billion for the quarter, compared to analyst estimates of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. On average, equities research analysts forecast that Fresenius SE & Co. will post 1.03 EPS for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, June 23rd. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.